StockData

GRI Bio vs Rein Therapeutics

GRI and RNTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GRI and RNTX compare

Rein Therapeutics is the larger company, worth 10 times as much as GRI Bio ($30.7M against $3.0M).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGRIRNTX
Size and price
Market cap$3.0M$30.7M
Share price$1.35$0.356
Change, 1 year−97.1%−71.5%
Change, 5 years−100%−97.3%
Beta (5Y)1.182.30
Employees410
StockData Score
Total score66
Valuation score11
Growth score00
Performance score00
Health score55
Dividend score00
Valuation
P/B0.3× (better)0.6×
Profitability
Return on equity−142%−96.4% (better)
Return on invested capital–−145%
Financial health
Debt / equity0.000.00
Current ratio10.30 (better)4.27
Altman Z-score−6.93 (better)−8.96
Piotroski F-score3 (better)2
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Buyback yield–−179%
Shareholder yield0.00% (better)−179%
Ownership
Held by institutions4.3%47.3%
Held by insiders26.2%9.6%
Insider net buying, 12 months–$74.7K
Short interest, % of float4.1%0.91%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.